BREAKING NEWS

Israel's MediWound signs $112m. deal in US for burn treatment

By REUTERS

SEPTEMBER 30, 2015 15:23

Israel-based MediWound has signed a five-year, $112 million contract with the US authority that handles public health medical emergencies to further develop and buy the company's drug treatment for severe burns.

Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said in a statement that the deal with the Biomedical Advanced Research and Development Authority would raise preparedness for mass-casualty incidents.

The US body would also help MediWound get approval for its drug NexoBrid, a topical treatment that removes damaged tissue, from the Food and Drug Administration, Clal said.

Ultra-Orthodox youths stopped by Palestinian police

By WALLA!

04/25/2024 02:34 AM

Members of hostages families block humanitarian aid trucks

By WALLA!

04/25/2024 02:07 AM

Coalition vessel engaged anti-ship ballistic missile launched from Yemen

By REUTERS

04/25/2024 01:42 AM

Karhi slams the attorney-general for 'trampling' on the law

By JERUSALEM POST STAFF

04/24/2024 11:28 PM